Entacapone and Muscle Atrophy
Author Information
Author(s): Zeng Rong, Xu Hanbing, Wu Mingzheng, Zhou Xianlong, Lei Pan, Yu Jiangtao, Wang Pinyi, Ma Haoli, Zhao Yan
Primary Institution: Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
Hypothesis
This study aims to explore the effects of entacapone as a potential therapeutic strategy against muscle atrophy.
Conclusion
Entacapone is a promising therapeutic candidate for muscle atrophy, functioning through the reduction of oxidative stress, proteolysis, and lipid aggregation.
Supporting Evidence
- Entacapone reduced Atrogin-1 levels by 84.4% compared to the Dex group.
- Entacapone significantly increased GSH-PX content by 385.6% compared to the Dex-treated group.
- Entacapone effectively reduced the Dex-induced increase in MDA content by 63.98%.
- Entacapone mitigated the decline in diaphragm muscle strength and myofiber CSA in mice.
- Entacapone alleviated lipid accumulation in the gastrocnemius muscle of hyperlipidemic mice.
Takeaway
Entacapone is a medicine that helps prevent muscle loss by reducing stress and damage in muscles.
Methodology
The study used in vitro C2C12 cells and four murine models to evaluate the effects of entacapone on muscle atrophy.
Potential Biases
The unbalanced sample sizes may influence statistical analyses.
Limitations
The induction of muscle atrophy in C2C12 myotubes may not fully replicate the complexity of muscle atrophy in vivo.
Participant Demographics
Male C57BL/6J and APOE−/− mice aged 6–8 weeks were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website